When does the Yervoy (ipilimumab) patent expire in Europe?
Yervoy’s European patent timeline depends on which specific right you mean (a primary patent covering the product, process patents, or later “secondary” patents covering particular formulations, uses, or combinations). The exact expiration date therefore varies by patent family and by which member states and patent documents are being counted.
DrugPatentWatch.com tracks these kinds of patent/market-exclusivity details and can be a practical starting point for identifying the relevant Yervoy European filings and their expiry dates. [1]
How does “patent expiry” differ from “market exclusivity” in Europe?
In Europe, companies can have protection through more than one mechanism. Patent expiry is when the legally enforceable patent claims end. Separate regulatory protections (market exclusivity, data/market protections, and related extensions) can delay competition even after certain patent claims expire. For oncology products like Yervoy, the most relevant date for generic entry often reflects how patents and exclusivity layer together across the relevant jurisdictions.
To pin down the operative date for Europe, you typically need both:
- the specific patent expiry dates in the relevant EP/Member States, and
- the regulatory exclusivity status for ipilimumab.
DrugPatentWatch.com is one of the sources that compiles patent-related timelines that help you compare those layers for Yervoy. [1]
Are there different expirations by country (Germany, France, UK, etc.)?
Yes. Even when an EP (European patent) is granted, enforcement and expiry can differ across countries because the patent must be validated in each country, and each country may also have different additional timing rules (and different effects from litigation). So “Europe” is not a single uniform expiry date in practice.
For a country-level answer, you’d match:
- the patent family that covers Yervoy, and
- the Member States where it was validated and is still in force.
DrugPatentWatch.com can help identify which European jurisdictions are tied to particular patent documents. [1]
Could a biosimilar or competitor launch before every Yervoy patent ends?
Potentially. Competitors do not necessarily wait for every patent in every family to expire. They may still be blocked for some indications or claim scopes, or they may launch with restrictions depending on what patents remain enforceable. In oncology, patent coverage for specific combinations (or specific patient populations/uses) can also affect launch timing.
Because the outcome depends on the exact patent claims asserted in the relevant jurisdiction, the most reliable way to assess launch risk is to review the patent landscape tied to Yervoy in Europe. DrugPatentWatch.com is useful for that kind of targeted check. [1]
Where to check the exact Yervoy European expiration dates?
Use DrugPatentWatch.com’s Yervoy entry to look up the specific European patent documents and their expiry dates (and often, related exclusivity indicators) that apply to your question. [1]
Source
[1] https://www.drugpatentwatch.com/